Search research articles
Contact Us
Filters
Showing results (101-110 of 125) with videos related to
Page
of 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
Beata Holkova, Adriana Zingone, Maciej Kmieciak, et al.
Blood
|
May 10, 2024
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma
Anthony M Cirrincione, Alexandra M Poos, Bachisio Ziccheddu, et al.
Blood Advances
|
October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
Ross S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
American Journal of Hematology
|
October 2, 2019
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma
Even H Rustad, Kristine Misund, Elsa Bernard, et al.
Blood Advances
|
February 17, 2026
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM
Kylee H Maclachlan, Carlyn Rose Tan, Tala Shekarkhand, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 27, 2020
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
Sarah A Holstein, Alan Howard, David Avigan, et al.
Blood Cancer Discovery
|
October 18, 2021
Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
Malin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis
Eric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.
Research Square
|
June 17, 2024
Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma
Malin Hultcrantz, Hani Hassoun, Neha Korde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenance
Ross S Firestone, Anish K Simhal, Devin McAvoy, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 125) with videos related to
Sort By:
Page
of 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
Beata Holkova, Adriana Zingone, Maciej Kmieciak, et al.
Blood
|
May 10, 2024
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma
Anthony M Cirrincione, Alexandra M Poos, Bachisio Ziccheddu, et al.
Blood Advances
|
October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
Ross S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
American Journal of Hematology
|
October 2, 2019
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma
Even H Rustad, Kristine Misund, Elsa Bernard, et al.
Blood Advances
|
February 17, 2026
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM
Kylee H Maclachlan, Carlyn Rose Tan, Tala Shekarkhand, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 27, 2020
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
Sarah A Holstein, Alan Howard, David Avigan, et al.
Blood Cancer Discovery
|
October 18, 2021
Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
Malin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis
Eric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.
Research Square
|
June 17, 2024
Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma
Malin Hultcrantz, Hani Hassoun, Neha Korde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenance
Ross S Firestone, Anish K Simhal, Devin McAvoy, et al.
Page
of 13